Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive Chemotherapy for Advanced Breast Cancer After Standard Treatment
NCT07088263Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2025
- Primary completion
- Jul 2027
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 3 trial of gemcitabine, vinorelbine, eribulin, utidelone in breast cancer, sponsored by Sun Yat-sen University. Started Sep 2025; status: recruiting.
02
Drugs
gemcitabinevinorelbineeribulinutidelone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07088263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07088263.